Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
No edit summary
No edit summary
 
(47 intermediate revisions by 4 users not shown)
Line 89: Line 89:
|
|
|-
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff
| || || || ||FQR|| ||
|10/14/25|| || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 509: Line 509:
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|Samreen Mehak (trainee), Malini Sathanoori
|3/2/2026
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 839: Line 839:
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|Disease
|Riku Das, PhD
|2/19/2026
|5/20/2026
|Pending
|
|
|
|Normally FQR, but Katie Schieffer instead
|
|
|
|FQR
|
|
|
|
Line 1,031: Line 1,031:
|
|
|Check reference format
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Line 1,095: Line 1,111:
|Previously within myeloid section under JH/MS editors
|Previously within myeloid section under JH/MS editors
|-
|-
!Disease (5th Edition)
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
!Page Type
|Disease
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|
|
|
|
|
|
Line 1,384: Line 1,384:
|01/24/2022. Emailed 5/1/2025, no response
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|Date completed by author: 01/24/2022
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|
|To be covered in B-ALL, NOS
|
|
|
|
Line 1,403: Line 1,419:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|
|
|
|
|'''Complete'''
|
|11/21/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
Line 1,419: Line 1,435:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|
|
|
|
|
|'''Complete'''
|11/21/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
Line 1,435: Line 1,451:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Holli Drendel
|Holli Drendel, PhD
|Nov 11/2025
|
|
|
|Pending
|?Complete? Looks like tables need more editing.
|
|
|SK
|SK
Line 1,448: Line 1,464:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Karin Miller, MD
|
|10/9/2025
|
|12/5/2025
|
|
|
|
Line 1,483: Line 1,483:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|Mark Evans, MD (University of California, Irvine) and Kilannin Krysiak
|Mark G. Evans, MD
|0/1/2025
|10/1/2025
|
|11/17/2025
|Pending
|'''Complete'''
|
|11/8/2025
|SK
|SK
|
|2/14/2026
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
Line 1,499: Line 1,499:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Gokce A. Toruner, MD, PhD
|10/9/2025
|11/5/2025
|Pending
|
|
|
|SK
|
|
|SK
|
|
|
|
Line 1,515: Line 1,515:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Gokce A. Toruner, MD, PhD
|
|10/8/2025
|
|12/1/2025
|
|Pending
|
|
|SK
|SK
Line 1,531: Line 1,531:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Lei Zhang;
|Lei Zhang, PhD
Michelle Fan (trainee)
Michelle Fan (trainee)
|8/8/2024
|10/10/2025
|
|12/22/2025
|Pending
|Pending
|
|
Line 1,548: Line 1,548:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|10/1/2025
|
|
|
|Pending
|
|
|SK
|SK
Line 1,564: Line 1,564:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|10/1/2025
|
|
|
|Pending
|
|
|SK
|SK
Line 1,580: Line 1,580:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Disease
|Aiko Otsubo
|Aiko Otsubo, PhD
|6/25/2024
|10/10/2025
|
|11/24/2025
|Pending
|'''Complete but needs a few edits'''
|
|11/11/2025
|SK
|SK
|
|2/14/2026
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 1,596: Line 1,596:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang;
|Lei Zhang, PhD
Michelle Fan (trainee)
|10/10/2025
|8/8/2024
|12/22/2025
|
|Pending
|Pending
|
|
Line 1,612: Line 1,611:
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|Disease  
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|SK
|
|
|
|
Line 1,618: Line 1,623:
|
|
|
|
|SK
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
!Disease (5th Edition)
!Disease (5th Edition)
Line 1,644: Line 1,643:
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
|ISSUE- FIX
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
 
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
 
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
 
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX




Line 1,661: Line 1,675:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
Line 1,700: Line 1,730:
|
|
|-
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||Sriharikrishnaa S
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
| 4/10/2026|| || Pending|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,710: Line 1,740:
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|
|PENDING
|
|
|
|
|SG
|SG
Line 1,726: Line 1,756:
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|
|PENDING
|Sent e-mail to prev authors no reply
|
|
|
|SG
|SG
|
|
|Email sent to request to update 2024
|Email sent to request to update 2024. Sent e-mail to prev authors no reply.
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
Line 1,742: Line 1,772:
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|Disease
|Pallavi Khattar
|3/2/2026
|
|
|PENDING
|
|
|Sent e-mail to prev authors no reply
|SG
|
|
|
|Email sent to request to update 2024. Sent e-mail to prev authors no reply
|SG
|
|Email sent to request to update 2024
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Line 1,904: Line 1,934:
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|Sriharikrishnaa S
|4/10/2026
|
|
|
|Pending
|
|
|
|
|SG
|SG
Line 2,346: Line 2,376:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Line 2,402: Line 2,416:
|Prior Notes (4th Edition)
|Prior Notes (4th Edition)
|-
|-
|
!Disease (5th Edition)
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
----<br />
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
----<br />
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
----<br />
!Associate Editor
|
!Date of Last Editor Review (5th Edition)
----<br />
!Notes (5th Edition)
|
!Correlated Prior Disease Name (4th Edition)
----<br />
!Correlated Prior Author (4th Edition)
|
!Prior Content Status (4th Edition)(Pending or Complete)
----<br />
!Prior Date of Last Editor Review (4th Edition)
|
!Prior Notes (4th Edition)
----<br />
|-
|
| colspan="15" |
----<br />
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,441: Line 2,443:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
Karin Miller, MD
|
|3/25/2024
| ||
| || || ||SK|| ||
| || || ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,470: Line 2,472:
|
|
|
|
|Pending
|
|
|
|SK
|SK
Line 2,483: Line 2,485:
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Parastou Tizro, MD (trainee);
|Parastou Tizro, MD;
Celeste Eno, PhD
Celeste Eno, PhD; Sumire Kitahara, MD
|3/17/2024
|9/23/2025
|
|11/4/2025
|Complete
|'''Complete'''
|6/24/2024
|11/4/2025
|SK
|SK
|7/1/2024
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 2,497: Line 2,499:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|9/24/2025
|6/30/24
|12/9/2025
|Pending
|Pending
| ||SK|| ||
| ||SK|| ||
Line 2,528: Line 2,514:
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
Michelle Don, MD, MS
Michelle Don, MD, MS
|3/17/2024
|9/24/2025
|6/30/24
|12/9/2025
|Pending
|'''Complete'''
| ||SK|| ||
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Michelle Don, MD
Line 2,551: Line 2,537:
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,558: Line 2,545:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|7/1/2024||8/31/2024
|Pending
|Pending
| ||SK|| ||
| ||SK|| ||
Line 2,569: Line 2,555:
|
|
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
!Disease (5th Edition)
|3/19/2024
!Page Type
| ||Pending
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
| ||SK|| ||
!Date Assigned to Author (5th Edition)
|NEW (No Prior)
!Target Completion Date (5th Edition)
|NEW (No Prior)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Abdelrahman Dabash
(trainee) and Ian King, PhD
|1/6/2026
| 2/3/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,582: Line 2,585:


Andrew Siref, MD
Andrew Siref, MD
|4/12/2024
|10/14/2025
| ||Pending
|11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,593: Line 2,597:
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,603: Line 2,607:
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,614: Line 2,618:
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,623: Line 2,627:
|
|
|-
|-
!Disease (5th Edition)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
!Page Type
Katelyn Swanson, DO (trainee)
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|11/19/2025
!Date Assigned to Author (5th Edition)
|12/19/2025
!Target Completion Date (5th Edition)
|'''Complete'''
!Content Status (5th Edition)(Pending or Complete)
| 1/6/2026||SK|| 1/6/2026||
!Date Completed by Author (5th Edition)
|NEW (No Prior)
!Associate Editor
|NEW (No Prior)
!Date of Last Editor Review (5th Edition)
|NEW (No Prior)
!Notes (5th Edition)
|NEW (No Prior)
!Correlated Prior Disease Name (4th Edition)
|NEW (No Prior)
!Correlated Prior Author (4th Edition)
|-
!Prior Content Status (4th Edition)(Pending or Complete)
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
|11/9/2025
|Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,663: Line 2,654:


Andrew Siref, MD
Andrew Siref, MD
|4/12/2024|| ||Pending
|10/14/2025||11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,677: Line 2,669:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
Line 2,695: Line 2,703:
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|10/14/2025
| ||Pending|| ||SK|| ||
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|Enteropathy-Associated T-cell Lymphoma
Line 2,705: Line 2,713:
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|10/14/2025
| ||Pending|| ||SK|| ||
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
Line 2,716: Line 2,724:
| || || || ||SK|| ||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|Derick Okwan MD, PhD (Stanford)  Sumire Kitahara MD (Cedars-Sinai)
|Complete
|Complete
|9/26/2022
|9/26/2022
Line 2,723: Line 2,731:
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
Michelle Don, MD, MS
Michelle Don, MD, MS
|3/19/2024
|9/24/2025
|6/30/24
|11/9/2025
|Complete
|'''Complete'''
|5/13/24||SK||10/18/24||
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Michelle Don, MD, MS
Line 2,732: Line 2,741:
|1/21/2021
|1/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);


Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,766: Line 2,759:
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Anaplastic Large Cell Lymphoma, ALK-Negative
Line 2,775: Line 2,768:
|-
|-
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|4/1/2024
|9/22/2025
| ||Pending|| ||SK|| ||
|1/1/2026
|Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Line 2,783: Line 2,777:
|
|
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
!Disease (5th Edition)
| ||Pending|| ||SK|| ||prior authors not available
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Hayk Simonyan (trainee) and Ian King||3/16/2026
|
| || ||SK|| ||prior authors not available; Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author.
|Angioimmunoblastic T-cell Lymphoma
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,791: Line 2,802:
|
|
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Ian King||3/16/2026
| ||Pending|| ||SK|| ||
|
| || ||SK|| ||Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author.
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,799: Line 2,811:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||Ian King
| || || || ||SK|| ||
| 3/16/2026|| || || ||SK|| ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
Line 2,808: Line 2,820:
|-
|-
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|6/25/2023
|10/14/2025
| || || ||SK|| ||
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,818: Line 2,832:
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
Andrew Siref, MD
|3/22/2024|| ||Pending|| ||SK|| ||
|10/14/2025|| ||Pending|| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,825: Line 2,839:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc;
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
Teodora Popa (resident)
|1/6/2026
|3/19/2024
| 2/3/2026||Complete
| ||Pending
| 1/27/2026||SK|| 2/14/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,842: Line 2,855:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
Line 2,868: Line 2,865:
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| 11/17/2025||'''Complete'''
| 11/17/2025||SK|| 2/14/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,877: Line 2,875:
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||prior authors not available
| 11/17/2025||'''Complete'''
| 11/18/2025||SK|| 2/14/2026||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Line 2,883: Line 2,882:
|11/21/2021
|11/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Line 2,978: Line 2,993:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
Line 3,042: Line 3,041:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Retrieved from "https://content.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"